ArticleJournal of the National Cancer Institute2025
Assessing the effect of the COVID-19 pandemic on 1-year cancer survival in the United States.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Impact of the COVID-19 pandemic on cancer incidence, stage, mortality, and short-term survival in Ireland: a population-based analysis.ESMO real world data and digital oncology · 2026Article
- Survival Outcomes and Machine Learning-Based Prediction of 12-Month Mortality in Glioblastoma Before and During the COVID-19 Pandemic: A SEER Population-Based Study.Medicina (Kaunas, Lithuania) · 2026Article
- Observational
- Racial Disparities in Time to Treatment of Pancreatic Adenocarcinoma During the COVID-19 Era: A Retrospective Database Analysis.Health science reports · 2026Article
- The COVID-19 pandemic has not influenced survival outcomes of head and neck cancer squamous cell carcinomas in the West of Scotland: a retrospective cohort study.BJC reports · 2026Article
- Minimal Impact of COVID-19 on One-Year Mortality on US Patients with Cancer Diagnosed Early during the Pandemic.Cancer research communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The COVID-19 pandemic had a substantial impact on health-care delivery. We used the Surveillance, Epidemiology, and End Results (SEER) data to assess changes in 1-year relative survival and competing risk probabilities of cancer and non-cancer death for patients diagnosed in 2018 Q2 (pre-pandemic) and 2020 Q2 (pandemic). For all cancer sites combined, 1-year relative survival declined from 82.3% in 2018 Q2 to 77.5% in 2020 Q2, with the steepest declines seen in stomach, leukemia, and liver cancers. However, survival improved nearing pre-pandemic levels during 2020 Q3. Competing risk survival measures revealed that the decline in 1-year survival was driven by increases in both the probability of dying of cancer (rising from 15.4% to 19.2%) and of other causes, including COVID-19 (rising from 3.8% to 5.2%). The pandemic led to substantial declines in survival and increased mortality from both cancer and other causes for patients diagnosed in 2020 Q2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.